Radiopharm Theranostics Ltd
For the period ended Aug 28, 2026. Filed Aug 28, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Aug 28, 2026 · Filed Aug 28, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Statement of changes in equity
Radiopharm Theranostics Limited Statement of changes in equity For the year ended 30 June 2026
| Attributable to owners of Radiopharm Theranostics Limited | ||||||
|---|---|---|---|---|---|---|
| Consolidated | Share Capital | Other equity | Other reserves | Accumulated losses | Non-controlling interest | Total equity |
| $ | $ | $ | $ | $ | $ | |
| Balance at 1 July 2024 | 100,681,716 | 849,544 | 37,930,072 | (111,338,770) | (769,276) | 27,353,286 |
| Loss after income tax expense for the year | - | - | - | (36,703,089) | (1,639,368) | (38,342,457) |
| Other comprehensive income for the year, net of tax | - | - | 464,034 | - | - | 464,034 |
| Total comprehensive income for the year | - | - | 464,034 | (36,703,089) | (1,639,368) | (37,878,423) |
| Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs(note 9) | 74,915,537 | - | (23,885,229) | - | - | 51,030,308 |
| Issue of options | - | - | 2,157,778 | - | - | 2,157,778 |
| Issue of shares for milestone completion | 741,400 | - | - | - | - | 741,400 |
| Equity-settled payments | 219,840 | - | (231,115) | - | - | (11,275) |
| Expiration of options | - | - | (2,797,451) | 2,797,451 | - | - |
| Forfeiture of options | - | - | (221,170) | - | - | (221,170) |
| Cancellation of shares to be issued | - | - | (300,000) | - | - | (300,000) |
| Increase in ownership in RAD Ventures | - | - | - | (488,544) | 488,544 | - |
| - | - | - | - | - | - | |
| Balance at 30 June 2025 | 176,558,493 | 849,544 | 13,116,919 | (145,732,952) | (1,920,100) | 42,871,904 |
The above statement of changes in equity should be read in conjunction with the accompanying notes
Radiopharm Theranostics Limited Statement of changes in equity For the year ended 30 June 2026
| Attributable to owners of Radiopharm Theranostics Limited | ||||||
|---|---|---|---|---|---|---|
| Consolidated | Share Capital | Other equity | Other reserves | Accumulated losses | Non-controlling interest | Total equity |
| $ | $ | $ | $ | $ | $ | |
| Balance at 1 July 2025 | 176,558,493 | 849,544 | 13,116,919 | (145,732,952) | (1,920,100) | 42,871,904 |
| Loss after income tax expense for the year | - | - | - | (55,149,150) | (1,801,344) | (56,950,494) |
| Other comprehensive income for the year, net of tax | - | - | 621,440 | - | - | 621,440 |
| Total comprehensive income for the year | - | - | 621,440 | (55,149,150) | (1,801,344) | (56,329,054) |
| Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs (note 9) | 33,374,878 | - | - | - | - | 33,374,878 |
| Issue of options | - | - | 2,740,119 | - | - | 2,740,119 |
| Expiration of options | - | - | (1,730,159) | 1,730,159 | - | - |
| Forfeiture of options | - | - | (334,164) | - | - | (334,164) |
| Increase in ownership in RAD Ventures | - | - | - | (1,357,918) | 1,357,918 | - |
| Derecognition of Pharma15 | - | (849,544) | - | 849,544 | - | - |
| Balance at 30 June 2026 | 209,933,371 | - | 14,414,155 | (199,660,317) | (2,363,526) | 22,323,683 |
The above statement of changes in equity should be read in conjunction with the accompanying notes
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.